For example, EGFR tyrosine kinase inhibitors (e.g., gefitinib, erlotinib, and afatinib) and ALK tyrosine kinase inhibitors (e.g., crizotinib, ceritinib) have demonstrated superior objective response rates and significant better progression-free survival in NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements than conventional one-fit-all chemotherapy (3, 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.